These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2491929)

  • 21. Hemophiliacs with inhibitors: therapeutic options.
    Roberts HR
    N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-factor VIII anamnesis after factor IX complex.
    Palascak JE; Shapiro SR
    N Engl J Med; 1977 Dec; 297(25):1403. PubMed ID: 927458
    [No Abstract]   [Full Text] [Related]  

  • 23. Antithrombin antigen of high molecular weight associated with neoantigen in hemophilic plasma after factor IX concentrate therapy.
    Hultin MB; Abildgaard U
    Thromb Res; 1987 Jan; 45(2):175-82. PubMed ID: 3105116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and thrombogenicity of factor IX concentrate.
    Sakuragawa N; Takahashi K; Itoh M; Matsuoka M
    Bibl Haematol; 1977; 44():88-93. PubMed ID: 617788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S; Jørgensen J
    Acta Med Scand; 1978; 203(6):471-6. PubMed ID: 665313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs' immune status and blood component usage.
    Jason J; McDougal JS; Holman RC; Stein SF; Lawrence DN; Nicholson JK; Dixon G; Doxey M; Evatt BL
    JAMA; 1985 Jun; 253(23):3409-15. PubMed ID: 2987559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-A in factor VIII concentrate: a cause of severe hemolysis in a patient with acquired factor VIII:C antibodies.
    Hach-Wunderle V; Teixidor D; Zumpe P; Kühnl P; Scharrer I
    Infusionstherapie; 1989 Jun; 16(3):100-1. PubMed ID: 2503450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to activated F IX concentrate (FEIBA).
    Stenbjerg S; Jorgensen J
    Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption.
    Gjörstrup P; Berntorp E; Larsson L; Nilsson IM
    Vox Sang; 1991; 61(4):244-50. PubMed ID: 1776241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
    Fukui H; Fujimura Y; Takahashi Y; Mikami S; Yoshioka A
    Thromb Res; 1981 Apr 1-15; 22(1-2):177-84. PubMed ID: 6794176
    [No Abstract]   [Full Text] [Related]  

  • 34. Letter: Rising factor VIII inhibitor titers after Konyne factor IX complex.
    Kasper CK; Feinstein DI
    N Engl J Med; 1976 Aug; 295(9):505-6. PubMed ID: 59902
    [No Abstract]   [Full Text] [Related]  

  • 35. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
    Kelly P; Penner JA
    JAMA; 1976 Nov; 236(18):2061-4. PubMed ID: 989788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].
    Weisser J
    Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor VIII inhibitor treatment with high doses of F VIII.
    Stenbjerg S; Ingerslev J; Zachariae E
    Thromb Res; 1984 Jun; 34(6):533-9. PubMed ID: 6429891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induced immunotolerance in factor VIII inhibitor patients.
    Brackmann HH
    Prog Clin Biol Res; 1984; 150():181-95. PubMed ID: 6431426
    [No Abstract]   [Full Text] [Related]  

  • 40. Blood safety and the choice of anti-hemophilic factor concentrate.
    Valentino LA; Oza VM
    Pediatr Blood Cancer; 2006 Sep; 47(3):245-54. PubMed ID: 16724312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.